Nilotinib Induced Keratosis Pilaris in a Female With Chronic Myeloid Leukemia

Bibliographic Details
Published in:	Dermatology Practical & Conceptual
Main Authors:	Ranjana Beniwal, Akriti Agrawal
Format:	Article
Language:	English
Published:	Mattioli1885 2024-04-01
Online Access:	http://dpcj.org/index.php/dpc/article/view/3923

Similar Items

Nilotinib-Induced Keratosis Pilaris
by: Wai Mun Sean Leong, et al.
Published: (2016-04-01)

Second-generation Tyrosine Kinase Inhibitors Nilotinib- and Dasatinib-induced Keratosis Pilaris: A Case Report and Review of the Literature
by: Hussein M. Alshamrani, et al.
Published: (2024-07-01)

Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
by: Tanawatt Kootiratrakarn, et al.
Published: (2015-01-01)

Extending the reach of nilotinib in chronic myeloid leukemia
by: Michael J. Mauro
Published: (2014-07-01)

Generalized keratosis pilaris induced by testosterone injections in patient with CHARGE syndrome
by: Fares A. Alkhayal, et al.
Published: (2023-04-01)

Keratosis pilaris caused by dupilumab for the treatment of bronchial asthma
by: Yuka Shibata, et al.
Published: (2021-08-01)

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
by: Mario Annunziata
Published: (2015-10-01)

Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia
by: Min Jeong Kim
Published: (2021-12-01)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Keratosis pilaris on TikTok: A cross-sectional analysis of trending content
by: Meghan R. Mansour, BS, et al.
Published: (2022-09-01)

Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia
by: Justine Chan, et al.
Published: (2019-01-01)

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
by: Meenakshi Sachdeva, et al.
Published: (2023-10-01)

Keratosis Pilaris Unveiled: Insights into its Origin, Management Strategies and Research Frontiers
by: Komalpreet Kaur, et al.
Published: (2025-09-01)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
by: Husam N. Al-Dubai, et al.
Published: (2020-06-01)

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
by: Adam Olshen, et al.
Published: (2014-11-01)

Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia
by: Mert Tokatlı, et al.
Published: (2024-03-01)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
by: Güldane Seval, et al.
Published: (2017-05-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
by: Francesca Palandri, et al.
Published: (2009-12-01)

Nilotinib-Induced Unilateral Renal Artery Stenosis: A Complication Prompting Treatment-Free Remission in Chronic Myeloid Leukemia
by: Mitchell C. Boshkos, et al.
Published: (2025-01-01)

Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response
by: Shifang Wang, et al.
Published: (2020-07-01)

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
by: Harnicar S, et al.
Published: (2014-08-01)

Dermoscopy of a Rare Case of Porokeratotic Eccrine Ostial and Dermal Duct Nevus
by: Ranjana Beniwal, et al.
Published: (2025-04-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
by: Delphine Rea, et al.
Published: (2014-07-01)

S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA
by: F. Pane, et al.
Published: (2022-06-01)

Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq
by: Ahmed Mjali, et al.
Published: (2022-06-01)

Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
by: Tayfur Toptas, et al.
Published: (2025-12-01)

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
by: Stein-Erik Gullaksen, et al.
Published: (2017-08-01)

Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature
by: Yasunobu Sekiguchi, et al.
Published: (2015-07-01)

Evaluation of Electrolytes Disturbances in Iraqi Chronic Myeloid Leukemia Patients treated with Nilotinib with Monitoring of Response by FISH Study
by: Baghdad Science Journal
Published: (2015-03-01)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021-11-01)

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
by: Timothy P. Hughes, et al.
Published: (2014-07-01)

Keratosis Pilaris Atrophicans Faciei: A Case Treated with 585 nm Diode Laser, a Novel Fractional Solid-State
by: Gönülal M, et al.
Published: (2023-12-01)

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients
by: Fausto Castagnetti, et al.
Published: (2016-10-01)